Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients

Kidney and Blood Pressure Research

Volumn 33, Issue 1, 2010, Pages 30-36

  Kalousová, Marta ^a   Jáchymová, Marie ^a   Germanová, Alexandra ^a   Kuběna, Aleš Antonín ^b   Tesa, Vladimíř ^a   Zima, Tomáš ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced glycation end products; Cardiovascular mortality; Glyoxalase; Hemodialysis; Polymorphisms; Receptor for advanced glycation end products; Soluble receptor for advanced glycation end products

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLYCINE;

ADULT; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; GENETIC PREDISPOSITION; HEMODIALYSIS; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY;

AGED; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE, CHRONIC; LACTOYLGLUTATHIONE LYASE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; UREMIA;

EID: 77950205352     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000285845     Document Type: Article

References (34)

1. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C: Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
2. Vanholder R, Baurmeister U, Brunet P, Cohen G, Glorieux G, Jankowski J, European Uremic Toxin Work Group: A bench to bedside view of uremic toxins. J Am Soc Nephrol 2008; 19: 863-870.
3. Thornalley PJ: Glyoxalase I - structure, function and a critical role in the enzymatic defence against glycation. Biochem Soc Trans 2003; 31: 1343-1348.
4. Roberts MA, Thomas MC, Fernando D, Macmillan N, Power DA, Ierino FL: Low molecular weight advanced glycation end products predict mortality in asymptomatic patients receiving chronic haemodialysis. Nephrol Dial Transplant 2006; 21: 1611-1617.
5. Wagner Z, Molnár M, Molnár GA, Tamaskó M, Laczy B, Wagner L, Csiky B, Heidland A, Nagy J, Wittmann I: Serum carboxymethyllysine predicts mortality in hemodialysis patients. Am J Kidney Dis 2006; 47: 294-300.
6. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D: Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule- 1 in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96: 1395-1403.
7. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM: N - (carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999; 274: 31740-31749.
8. Buetler TM, Leclerc E, Baumeyer A, Latado H, Newell J, Adolfsson O, Parisod V, Richoz J, Maurer S, Foata F, Piguet D, Junod S, Heizmann CW, Delatour T: N - -carboxymethyllysine- modified proteins are unable to bind to RAGE and activate an inflammatory response. Mol Nutr Food Res 2008; 52: 370-378.
9. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A: Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-15004.
10. Schmidt AM, Yan SD, Yan SF, Stern DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001; 108: 949-955.
11. Basta G: Receptor for advanced glycation end products and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 2008; 196: 9-21.
12. Sugaya K, Fukagawa T, Matsumoto K, Mita K, Takahashi E, Ando A, Inoko H, Ikemura T: Three genes in the human MHC class III region near the junction with the class II: gene for receptor of advanced glycosylation end products, PBX2 homeobox gene and a notch homolog, human counterpart of mouse mammary tumor gene int-3. Genomics 1994; 23: 408-419.
13. Thornalley PJ: The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 1990; 269: 1-11.
14. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y, Lalla E, Chitnis S, Monteiro J, Stickland MH, Bucciarelli LG, Moser B, Moxley G, Itescu S, Grant PJ, Gregersen PK, Stern DM, Schmidt AM: RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002; 3: 123-135.
15. Pettersson-Fernholm K, Forsblom C, Hudson BI, Perola M, Grant PJ, Groop PH, Finn- Diane Study Group: The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 2003; 52: 891-894.
16. Kanková K, Stejskalová A, Hertlová M, Znojil V: Haplotype analysis of the RAGE gene: identification of a haplotype marker for diabetic nephropathy in type 2 diabetes mellitus. Nephrol Dial Transplant 2005; 20: 1093-1102.
17. Falcone C, Campo I, Emanuele E, Buzzi MP, Zorzetto M, Sbarsi I, Cuccia M: Relationship between the -374 T/A RAGE gene polymorphism and angiographic coronary artery disease. Int J Mol Med 2004; 14: 1061-1064.
18. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C, Zorzetto M, Sbarsi I, Cuccia M: 374 T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 2005; 354: 111-116.
19. Kalousová M, Germanová A, Jáchymová M, Mestek O, Tesar V, Zima T: A419C (E111A) polymorphism of the glyoxalase I gene and vascular complications in chronic hemodialysis patients. Ann NY Acad Sci 2008; 1126: 268-271.
20. Kalousová M, Jáchymová M, Mestek O, Hodková M, Kazderová M, Tesar V, Zima T: Receptor for advanced glycation end products - soluble form and gene polymorphisms in chronic haemodialysis patients. Nephrol Dial Transplant 2007; 22: 2020-2026.
21. Kanková K, Stejskalová A, Pácal L, Tschoplová S, Hertlová M, Krusová D, Izakovicová- Hollá L, Beránek M, Vask? A, Barral S, Ott J: Genetic risk factors for diabetic nephropathy on chromosomes 6p and 7q identified by the set-association approach. Diabetologia 2007; 50: 990-999.
22. Hudson BI, Stickland MH, Futer TS, Grants PJ: Effect of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 2001; 50: 1505-1511.
23. Picheth G, Costantini CO, Pedrosa FO, Leme da Rocha Martinez T, Maltempi de Souza E: The -374A allele of the receptor for advanced glycation end products gene promoter is a protective factor against cardiovascular lesions in type 2 diabetes mellitus patients. Clin Chem Lab Med 2007; 45: 1268-1272.
24. Dos Santos KG, Canani LH, Gross JL, Tschiedel B, Pires Souto KE, Roisenberg I: The -374A allele of the receptor for advanced glycation end products gene is associated with a decreased risk of ischemic heart disease in African-Brazilians with type 2 diabetes. Mol Genet Metab 2005; 85: 149-156.
25. Falcone C, Geroldi D, Buzzi MP, Emanuele E, Yilmaz Y, Fontana JM, Vignali L, Boiocchi C, Sbarsi I, Cuccia M: The -374T/A RAGE polymorphism protects against future cardiac events in nondiabetic patients with coronary artery disease. Arch Med Res 2008; 39: 320-325.
26. Hofmann MA, Yang Q, Harja E, Kedia P, Gregersen PK, Cupples LA, Schmidt AM, Hudson BI: The RAGE Gly82Ser polymorphism is not associated with cardiovascular disease in the Framingham offspring study. Atherosclerosis 2005; 182: 301-305.
27. Carroll L, Frazer IH, Turner M, Marwick MH, Thomas R: Receptor for advanced glycation end product glycine 82 serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Res Ther 2007; 9:R39.
28. Yoon SJ, Park S, Shim CY, Park CM, Ko YG, Choi D, Park HY, Oh B, Kim H, Jang Y, Chung N: Association of RAGE gene polymorphisms with coronary artery disease in the Korean population. Coron Artery Dis 2007; 18: 1-8.
29. Degaffe GH, Vander Jagt DL, Bobelu A, Bobelu J, Neha D, Waikaniwa M, Zager P, Shah VO: Distribution of glyoxalase I polymorphism among Zuni Indians: the Zuni Kidney Project. J Diabetes Complications 2008; 22: 267-272.
30. Chen F, Wollmer MA, Hoerndli F, Münch G, Kuhla B, Rogaev EI, Tsolaki M, Papassotiropoulos A, Götz J: Role for glyoxalase I in Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 7687-7692.
31. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Ogura H, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K: Glyoxalase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialysis patient. Kidney Int 2001; 60: 2351-2359.
32. Bierhaus A, Nawroth P: Role of AGEs in pain and loss of pain perception. Abstract Book of the 9th International Symposium on the Maillard Reaction, 2007, p 41.
33. Thornalley PJ: Dietary AGEs and ALEs and risk to human health by their interaction with the receptor for advanced glycation end products - an introduction. Mol Nutr Food Res 2007; 51: 1107-1110.
34. Thornalley PJ, Rabbani N: Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009; 22: 400-404.